Loading
A phase 3 trial of Atezolizumab and Bevacizumab in advanced solid tumours, run by Hoffmann-La Roche, active and no longer recruiting.
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) is a phase 3 interventional study registered as NCT03148418 by Hoffmann-La Roche, with 382 participants enrolled, started 2017-09-20 and due to reach its primary completion in 2026-12-31. Interventions recorded: Atezolizumab and Bevacizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Flatiron Health (Roche), Atezolizumab, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Flatiron Health (Roche), Immune checkpoint inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/